These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11270932)

  • 1. Treatment of borderline personality disorder with mood instability with divalproex sodium: series of ten cases.
    Townsend MH; Cambre KM; Barbee JG
    J Clin Psychopharmacol; 2001 Apr; 21(2):249-51. PubMed ID: 11270932
    [No Abstract]   [Full Text] [Related]  

  • 2. Divalproex sodium as a treatment for borderline personality disorder.
    Wilcox JA
    Ann Clin Psychiatry; 1995 Mar; 7(1):33-7. PubMed ID: 8541935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The use of valproic acid in the treatment of borderline personality disorder].
    Hirschman S; Dolberg OT; Stern L; Grunhaus LJ
    Harefuah; 1997 Sep; 133(5-6):205-8. PubMed ID: 9461692
    [No Abstract]   [Full Text] [Related]  

  • 4. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder.
    Kavoussi RJ; Coccaro EF
    J Clin Psychiatry; 1998 Dec; 59(12):676-80. PubMed ID: 9921702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study.
    Frankenburg FR; Zanarini MC
    J Clin Psychiatry; 2002 May; 63(5):442-6. PubMed ID: 12019669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Divalproex versus valproate in patients with bipolar disorder.
    Kablinger AS; Czerwinski WP; Minagar A
    J Clin Psychopharmacol; 2004 Apr; 24(2):231-2. PubMed ID: 15206673
    [No Abstract]   [Full Text] [Related]  

  • 7. Appropriateness of plasma level determinations for lithium and valproate in routine care of psychiatric inpatients with affective disorders.
    Mann K; Hiemke C; Lotz J; Schmidt LG; Lackner KJ; Bates DW
    J Clin Psychopharmacol; 2006 Dec; 26(6):671-3. PubMed ID: 17110832
    [No Abstract]   [Full Text] [Related]  

  • 8. [Mood stabilizer in the psychopharmacotherapy of borderline personality disorder].
    Gescher DM; Malevani J
    Fortschr Neurol Psychiatr; 2009 Jul; 77(7):389-98. PubMed ID: 19455483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder.
    Hollander E; Swann AC; Coccaro EF; Jiang P; Smith TB
    Am J Psychiatry; 2005 Mar; 162(3):621-4. PubMed ID: 15741486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder.
    Reich DB; Zanarini MC; Bieri KA
    Int Clin Psychopharmacol; 2009 Sep; 24(5):270-5. PubMed ID: 19636254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lamotrigine and borderline personality disorder.
    Rizvi ST
    J Child Adolesc Psychopharmacol; 2002; 12(4):365-6. PubMed ID: 12625999
    [No Abstract]   [Full Text] [Related]  

  • 12. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder.
    Hollander E; Allen A; Lopez RP; Bienstock CA; Grossman R; Siever LJ; Merkatz L; Stein DJ
    J Clin Psychiatry; 2001 Mar; 62(3):199-203. PubMed ID: 11305707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release divalproex sodium for mood stabilization.
    Stoner SC; Dubisar BM; Lea JW; Marken PA; Ramlatchman LV; Reynolds JB
    Pharmacotherapy; 2004 Sep; 24(9):1147-53. PubMed ID: 15460175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on pharmacotherapy of borderline personality disorder.
    Zanarini MC
    Curr Psychiatry Rep; 2004 Feb; 6(1):66-70. PubMed ID: 14738708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extreme mood lability associated with systemic lupus erythematosus and stroke successfully treated with valproic acid.
    Himelhoch S; Haller E
    J Clin Psychopharmacol; 1996 Dec; 16(6):469-70. PubMed ID: 8959482
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group.
    Bowden CL; Calabrese JR; McElroy SL; Gyulai L; Wassef A; Petty F; Pope HG; Chou JC; Keck PE; Rhodes LJ; Swann AC; Hirschfeld RM; Wozniak PJ
    Arch Gen Psychiatry; 2000 May; 57(5):481-9. PubMed ID: 10807488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychiatric use and utility of divalproex sodium in Connecticut prisons.
    Kamath J; Temporini HD; Quarti S; Wanli Zhang ; Pagano KL; Demartinis N; Trestman RL
    Int J Offender Ther Comp Criminol; 2008 Jun; 52(3):358-70. PubMed ID: 17893206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of patient preference and side effects in patients switched from divalproex sodium delayed release to divalproex sodium extended release.
    Minirth FB; Neal V
    J Clin Psychopharmacol; 2005 Feb; 25(1):99-101. PubMed ID: 15643111
    [No Abstract]   [Full Text] [Related]  

  • 19. An open trial of valproate in borderline personality disorder.
    Stein DJ; Simeon D; Frenkel M; Islam MN; Hollander E
    J Clin Psychiatry; 1995 Nov; 56(11):506-10. PubMed ID: 7592502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Divalproex sodium in the treatment of aggressive behavior.
    Wilcox J
    Ann Clin Psychiatry; 1994 Mar; 6(1):17-20. PubMed ID: 7951640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.